O. Zenker

发表

Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac®) in chronic immune thrombocytopenic purpura

T. Robak, L. Aledort, A. Newland, 2007, Hematology.

Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

W. Robberecht, B. Tackenberg, C. Sommer, 2013, Journal of the peripheral nervous system : JPNS.

Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?

N. Riedemann, E. Giamarellos‐Bourboulis, M. Habel, 2018, The British journal of dermatology.

Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.

V. Wahn, B. Grimbacher, H. Peter, 2011, Clinical immunology.

Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

B. Grimbacher, M. Serban, S. Jolles, 2011, Journal of Clinical Immunology.

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency

S. Spector, J. Orange, R. Wasserman, 2010, Journal of Clinical Immunology.

Clinical efficacy of complement C5a inhibition by IFX‐1 in hidradenitis suppurativa: an open‐label single‐arm trial in patients not eligible for adalimumab

M. Argyropoulou, N. Riedemann, R. Guo, 2020, The British journal of dermatology.

Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura

T. Robak, M. Mazzucconi, P. Kiessling, 2009, Hematology.

Trough levels of 20% subcutaneous immunoglobulin (SCIG) when switching from SCIG

S. Jolles, B. Belohradsky, M. Borte, 2010 .

Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.

M. Rojavin, M. Berger, P. Kiessling, 2011, Clinical immunology.

Increased frequency of infections at the end of the IVIG dosing cycle: effect characterization from three Phase III studies

M. Rojavin, M. Berger, J. Baggish, 2012 .

Effect of mitoxantrone on MRI in progressive MS

S. Morrissey, H. Hartung, H. Krapf, 2005, Neurology.

Longitudinal changes in measles antibody titers in plasma donors and minimum antibody levels of immunoglobulin products for treatment of primary immunodeficiency

T. Simon, O. Zenker, P. Fitzgerald, 2018, Transfusion.

Efficacy and Safety of a New Intravenous Immunoglobulin Product in Patients with Chronic Immune Thrombocytopenic Purpura.

T. Robak, M. Mazzucconi, A. Salama, 2007 .

Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura

M. Mazzucconi, A. Salama, P. Kiessling, 2009, Hematology.

Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.

V. Wahn, B. Grimbacher, H. Peter, 2011, Clinical immunology.

Carimune NF Liquid is a Safe and Effective Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency Diseases

C. Cunningham-Rundles, F. Bonilla, J. Bichler, 2007, Journal of Clinical Immunology.